Archive: 07/11/2016

Checkpoint blockade helps only a subset of patients, why?

Although many cancer patients respond favorably to immunotherapies such as nivolumab and pembrolizumab, most patients do not. Blame for treatment failures is usually attributed to so-called "cold" tumors, those that do not ...

page 2 from 11